A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism
Phase of Trial: Phase III
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Dasiglucagon (Primary)
- Indications Congenital hyperinsulinism
- Focus Registrational; Therapeutic Use
- Sponsors Zealand Pharma
- 08 Jan 2019 Status changed from not yet recruiting to recruiting.
- 24 Dec 2018 Status changed from planning to not yet recruiting.
- 15 Nov 2018 According to a Zealand Pharma media release, the company expects to initiate this trial in Q4 2018, which is slightly later than the earlier announcement as the company is incorporating additional comments from FDA to simplify and improve the program.